Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy

No abstract is available for this paper.

• Publication year

  2009

• Venue

  CNS Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00023210-200923060-00004PMID 19480468
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy.

  2009cited by this paper
• Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications

  2008cited by this paper
• Psychosocial stress and pregnancy outcome.

  2008cited by this paper
• Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.

  2008cited by this paper
• Duration of antidepressant use during pregnancy and risk of major congenital malformations

  2008cited by this paper
• Maternal use of selective serotonin re‐uptake inhibitors and persistent pulmonary hypertension of the newborn

  2008cited by this paper
• Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: Population-based study

  2008cited by this paper
• Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.

  2008cited by this paper
• Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.

  2007cited by this paper
• Paroxetine in the first trimester and the prevalence of congenital malformations

  2007cited by this paper
• Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth.

  2007cited by this paper
• Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study

  2007cited by this paper
• CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure

  2007cited by this paper
• First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.

  2007cited by this paper
• Birth outcomes following prenatal exposure to antidepressants.

  2007cited by this paper
• First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.

  2007cited by this paper
• Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review

  2007cited by this paper
• Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy

  2007cited by this paper
• Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy.

  2007cited by this paper
• Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.

  2007cited by this paper
• Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.

  2007cited by this paper
• Teratogenicity of SSRIs--serious concern or much ado about little?

  2007cited by this paper
• Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn.

  2006cited by this paper
• Selective serotonin reuptake inhibitors and adverse pregnancy outcomes.

  2006cited by this paper
• Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

  2006cited by this paper
• Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.

  2006cited by this paper
• Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn

  2006cited by this paper
• Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations

  2006cited by this paper
• To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects

  2006cited by this paper
• Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications.

  2006cited by this paper
• Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn.

  2006cited by this paper
• Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials.

  2006cited by this paper
• Antidepressant drugs during pregnancy and infant congenital heart defect.

  2006cited by this paper
• Antidepressant Use during Pregnancy and the Rates of Spontaneous Abortions: A Meta-Analysis

  2005cited by this paper
• Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy

  2005cited by this paper
• The medical management of depression.

  2005cited by this paper
• Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.

  2005cited by this paper
• Pain Reactivity in 2-Month-Old Infants After Prenatal and Postnatal Selective Serotonin Reuptake Inhibitor Medication Exposure

  2005cited by this paper
• Depression during pregnancy.

  2005cited by this paper
• Fluoxetine during pregnancy: impact on fetal development.

  2005cited by this paper
• The Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Breast-feeding: A Review and Clinical Aspects

  2005cited by this paper
• Fluoxetine use in early pregnancy.

  2004cited by this paper
• Antepartum and postpartum depression: healthy mom, healthy baby.

  2004cited by this paper
• Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.

  2004cited by this paper
• Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy.

  2004cited by this paper
• Discontinuation syndrome following late pregnancy exposure to antidepressants.

  2004cited by this paper
• Serotonin and morphogenesis

  2004cited by this paper
• Neonate characteristics after maternal use of antidepressants in late pregnancy.

  2004cited by this paper
• Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

  2004cited by this paper
• Assessment and treatment of depression during pregnancy: an update.

  2003cited by this paper
• Serotonin and its transporter on proliferation of fetal heart cells

  2003cited by this paper
• Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy.

  2003cited by this paper
• Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions.

  2003cited by this paper
• Placental passage of antidepressant medications.

  2003cited by this paper
• Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.

  2003cited by this paper
• Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation

  2003cited by this paper
• Outcomes of prenatal antidepressant exposure.

  2002cited by this paper
• Perinatal outcome following third trimester exposure to paroxetine.

  2002cited by this paper
• Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics

  2002cited by this paper
• Citalopram in pregnancy and lactation

  2002cited by this paper
• Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study.

  2002cited by this paper
• Prolonged Prenatal Psychotropic Medication Exposure Alters Neonatal Acute Pain Response

  2002cited by this paper
• Serotonin and serotonin-like substances as regulators of early embryogenesis and morphogenesis

  2001cited by this paper
• Antepartum Depressive Symptomatology Is Associated With Adverse Obstetric and Neonatal Outcomes

  2001cited by this paper
• Hypernatraemia: why bother weighing breast fed babies?

  2001cited by this paper
• [Serious life events and congenital malformations. A national study with a complete follow-up].

  2001cited by this paper
• Neurotransmitters and neuromodulators during early human development.

  2001cited by this paper
• Antidepressant Discontinuation Syndromes

  2001cited by this paper
• Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression

  2000cited by this paper
• Serious life events and congenital malformations: a national study with complete follow-up.

  2000cited by this paper
• Birth outcomes following prenatal exposure to fluoxetine.

  2000cited by this paper
• Maternal life event stress and congenital anomalies.

  2000cited by this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors.

  2000cited by this paper
• Maternal distress and congenital malformations: do mothers of malformed fetuses have more problems?

  1999cited by this paper
• Pharmacologic treatment of depression during pregnancy.

  1999cited by this paper
• Delivery outcome after the use of antidepressants in early pregnancy

  1999cited by this paper
• Behavioral changes in developing mice after prenatal exposure to paroxetine (Paxil)

  1999cited by this paper
• Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo.

  1999cited by this paper
• Preclinical toxicological evaluation of sertraline hydrochloride.

  1998cited by this paper
• Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.

  1998cited by this paper
• Effect of prenatal diazepam, phenobarbital, haloperidol and fluoxetine exposure on foot shock induced aggression in rats.

  1998cited by this paper
• Preclinical toxicological evaluation of sertraline hydrochloride.

  1998cited by this paper
• Mouse 5‐HT2B Receptor‐mediated Serotonin Trophic Functions a

  1998cited by this paper
• Neurodevelopment of children exposed in utero to antidepressant drugs

  1997cited by this paper
• Birth outcomes in pregnant women taking fluoxetine.

  1996cited by this paper
• Serotonin reuptake inhibitor withdrawal.

  1996cited by this paper
• Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings.

  1995cited by this paper
• Maternal Depressive Symptoms and the Risk of Poor Pregnancy Outcome Review of the Literature and Preliminary Findings

  1995cited by this paper
• Depression During Pregnancy

  1995cited by this paper
• Serotonin regulates mouse cranial neural crest migration.

  1995cited by this paper
• Developmental Toxicology Studies of Fluoxetine Hydrochloride Administered Orally to Rats and Rabbits

  1994cited by this paper
• Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits.

  1994cited by this paper
• Antidepressant drug selection: criteria and options.

  1994cited by this paper
• A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats.

  1994cited by this paper
• The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation.

  1993cited by this paper
• Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)

  1993cited by this paper
• Serotonin and cardiac morphogenesis in the mouse embryo.

  1993cited by this paper
• The reproductive toxicology of paroxetine

  1989cited by this paper

• Drug-induced risk of depression: A 20-year real-world pharmacovigilance analysis based on the FAERS database

  2026cites this paper
• Adverse reactions associated with SSRIs and PD-1/PD-L1 inhibitors: a disproportionality analysis of the FDA Adverse Event Reporting System

  2024influential citation
• Efficacy of bright light therapy improves outcomes of perinatal depression: A systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• Beyond the Brain: Perinatal Exposure of Rats to Serotonin Enhancers Induces Long-Term Changes in the Jejunum and Liver

  2024cites this paper
• Development of the Placenta and Brain Are Affected by Selective Serotonin Reuptake Inhibitor Exposure During Critical Periods.

  2023cites this paper
• Poor Neonatal Adaptation After Antidepressant Exposure During the Third Trimester in a Geographically Defined Cohort

  2023cites this paper
• Case report of tokophobia

  2023cites this paper
• Hypersensitivity of Zebrafish htr2b Mutant Embryos to Sertraline Indicates a Role for Serotonin Signaling in Cardiac Development

  2022cites this paper
• Das Management akuter psychischer Erkrankungen in der Schwangerschaft

  2021cites this paper
• Characterization of pregnancies exposed to St. John's wort and their outcomes: a claims data analysis.

  2021cites this paper
• A smartphone-assisted brief online cognitive-behavioral intervention for pregnant women with depression: a study protocol of a randomized controlled trial

  2021cites this paper
• Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.

  2020cites this paper
• Antidepressant Paroxetine Exerts Developmental Neurotoxicity in an iPSC-Derived 3D Human Brain Model

  2020cites this paper
• Selective serotonin reuptake inhibitors’ passage into human milk of lactating women

  2019cites this paper
• Assessing low mood during pregnancy

  2019cites this paper
• Effect of Pregnancy on Paroxetine-Induced Adiposity and Glucose Intolerance in Mice

  2019cites this paper
• Longitudinal trajectories of antidepressant use in pregnancy and the postnatal period

  2018cites this paper
• Perinatal SSRI exposure permanently alters cerebral serotonin receptor mRNA in mice but does not impact adult behaviors

  2018cites this paper
• Passive Addiction and Teratogenic Effects

  2018cites this paper
• Maternal SSRIs experience and risk of ASD in offspring: a review.

  2018cites this paper
• Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

  2018cites this paper
• Chronic postnatal monoamine oxidase inhibition affects affiliative behavior in rat pupso

  2017cites this paper
• Neurodevelopmental Effects of Serotonin on the Brainstem Respiratory Network.

  2017cites this paper
• Effect of antidepressants use in pregnancy on foetus development and adverse effects in newborns.

  2017cites this paper
• Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study

  2017cites this paper
• Differential effects of perinatal exposure to antidepressants on learning and memory, acoustic startle, anxiety, and open‐field activity in Sprague‐Dawley rats

  2017cites this paper
• Cluster analysis profiling of behaviors in zebrafish larvae treated with antidepressants and pesticides.

  2017cites this paper
• Management of psychotropic drugs during pregnancy

  2016cites this paper
• Selective serotonin reuptake inhibitor exposure constricts the mouse ductus arteriosus in utero.

  2016cites this paper
• The Management of Bipolar Disorder During and After Pregnancy

  2016cites this paper
• Effects of maternal stress and perinatal fluoxetine exposure on behavioral outcomes of adult male offspring.

  2016cites this paper
• Of rodents and humans: A comparative review of the neurobehavioral effects of early life SSRI exposure in preclinical and clinical research

  2016cites this paper
• Perinatal exposure to the selective serotonin reuptake inhibitor citalopram alters spatial learning and memory, anxiety, depression, and startle in Sprague‐Dawley rats

  2016cites this paper
• Risk factors for poor neonatal adaptation after exposure to antidepressants in utero

  2015cites this paper
• Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.

  2015cites this paper
• Identifying and Assessing the Substance-Exposed Infant

  2015cites this paper
• Can Drug Effects Explain the Recent Temporal Increase in Atonic Postpartum Haemorrhage?

  2015cites this paper
• Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates

  2015cites this paper
• Effects of neonatal fluoxetine exposure on behavior across development in rats selectively bred for an infantile affective trait.

  2015cites this paper
• The neurodevelopmental effects of serotonin: a behavioural perspective.

  2015cites this paper
• Short report Open Access

  2015cites this paper
• Effects of Citalopram on Sutural and Calvarial Cell Processes

  2015cites this paper
• Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy – an epidemiological study using validated EUROCAT data

  2014cites this paper
• Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations

  2014cites this paper
• The effect of perinatal exposures on the infant: antidepressants and depression.

  2014cites this paper
• Prenatal exposure to antidepressants and language competence at age three: results from a large population‐based pregnancy cohort in Norway

  2014cites this paper
• Psychiatric neural networks and neuropharmacology: Selected advances and novel implications.

  2014cites this paper
• Management of neonatal abstinence syndrome in the newborn nursery.

  2014cites this paper
• Naturopathic Doctors’ Perspectives on Mental Health and Psychiatric Drugs: Results of a Pilot Survey

  2014cites this paper
• Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity‐score matched cohort in CPRD

  2013cites this paper
• Genetic and pharmacological manipulations of the serotonergic system in early life: neurodevelopmental underpinnings of autism-related behavior

  2013cites this paper
• Anxiety Disorders in Pregnancy and the Postpartum Period

  2013cites this paper
• Lack of serotonin reuptake during brain development alters rostral raphe-prefrontal network formation

  2013cites this paper
• Use of antidepressant medication in the United States during pregnancy, 2002-2010.

  2013cites this paper
• Long-Term Outcomes of Developmental Exposure to Fluoxetine: A Review of the Animal Literature

  2013cites this paper
• [The safety profile of escitalopram in pregnancy and breastfeeding].

  2013cites this paper
• In Vivo Genotoxicity Assessment of Sertraline by Using Alkaline Comet Assay and the Cytokinesis‐Block Micronucleus Assay

  2013cites this paper
• The use of psychotropic medication during pregnancy: how about the newborn?

  2013cites this paper
• Neonates and parents: neurodevelopmental perspectives in the neonatal intensive care unit and follow-up

  2013cites this paper
• CLINICAL REPORT Neonatal Drug Withdrawal

  2012cites this paper
• Efficacy of light therapy for perinatal depression: a review

  2012cites this paper
• Behavioural outcomes of perinatal maternal fluoxetine treatment.

  2012cites this paper
• Investigating outcomes associated with medication use during pregnancy: a review of methodological challenges and observational study designs.

  2012cites this paper
• The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review

  2012cites this paper
• Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation

  2012cites this paper
• Lasting effects of chronic fluoxetine treatment on the late developing rat brain: Age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI

  2012cites this paper
• Long term impact of prenatal exposure to SSRIs on growth and body weight in childhood: evidence from animal and human studies.

  2012cites this paper
• Neonatal Drug Withdrawal

  2012cites this paper
• Internet resources.

  2011cites this paper
• Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations.

  2011cites this paper
• Intensive cognitive-behavioural treatment for women with postnatal obsessive-compulsive disorder: a consecutive case series.

  2011cites this paper
• Monoamine Oxidase A Expression Is Vital for Embryonic Brain Development by Modulating Developmental Apoptosis*

  2011cites this paper
• Prenatal Cocaine Disrupts Serotonin Signaling-Dependent Behaviors: Implications for Sex Differences, Early Stress and Prenatal SSRI Exposure

  2011cites this paper
• Protocolo de actuación para el uso de psicofármacos en el embarazo

  2011cites this paper
• Investigating Outcomes Following the Use of Selective Serotonin Reuptake Inhibitors for Treating Depression in Pregnancy

  2011cites this paper
• Embryologie und Teratologie

  2011cites this paper
• Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

  2011cites this paper
• The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review.

  2011cites this paper
• Successful Treatment of Major Depression with Electroconvulsive Therapy in a Pregnant Patient with Previous Non-Response to Prefrontal rTMS

  2011cites this paper
• Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population

  2011cites this paper
• St. John's wort and S-adenosyl methionine as "natural" alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit?

  2011cites this paper
• Human Amniocytes Regulate Serotonin Levels by Active Uptake and Express Genes Suggestive of a Wider Role in Facilitating Neurotransmitter Regulation in the Fetal Environment

  2011cites this paper
• Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome

  2011cites this paper
• [Perinatal obsessive-compulsive disorder].

  2011cites this paper
• Medication-taking behaviour during pregnancy: is it appropriate?

  2010cites this paper
• An approach to the psychopharmacologic care of patients: antidepressants, antipsychotics, anxiolytics, mood stabilizers, and natural remedies.

  2010cites this paper
• New perspectives on the neurodevelopmental effects of SSRIs.

  2010cites this paper
• Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants

  2010cites this paper
• Serotonin, pregnancy and increased autism prevalence: is there a link?

  2010cites this paper
• Prenatal exposure to serotonin reuptake inhibitors: a case report

  2010cites this paper
• Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis

  2010cites this paper
• Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decade

  2010cites this paper
• Dépression et traitement antidépresseur pendant la grossesse : quels effets à long terme sur le sommeil de l’enfant ?

  2009cites this paper